26 Jun 2018 11:57
Motif Bio plc
("Motif Bio" or the "Company")
Exercise of Stock Options
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from a stock option holder to exercise options representing 125,736 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of 10.52p per option for total consideration of £13,231.00.
Application has been made for the 125,736 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 29 June 2018. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 296,660,243 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
For further information please contact:
Motif Bio plc | info@motifbio.com |
Graham Lumsden (Chief Executive Officer) | |
Peel Hunt LLP (NOMAD & BROKER) | + 44 (0)20 7418 8900 |
Dr Christopher Golden | |
Oliver Jackson | |
Northland Capital Partners Limited (BROKER) | +44 (0)203 861 6625 |
David Hignell/John Howes/Rob Rees | |
Walbrook PR Ltd. (UK FINANCIAL PR & IR) | +44 (0) 20 7933 8780 |
Paul McManus/Helen Cresswell/Lianne Cawthorne | |
MC Services AG (EUROPEAN IR) |
+49 (0)89 210 2280 |
Raimund Gabriel | raimund.gabriel@mc-services.eu |
Solebury Trout (U.S. IR) | + 1 (646) 378-2936 |
Meggie Purcell | mpurcell@troutgroup.com |
Russo Partners (U.S. PR) | +1 (858) 717-2310 or +1 (212) 845 4272 |
David Schull | david.schull@russopartnersllc.com |
Travis Kruse, Ph.D. | travis.kruse@russopartnersllc.com |